Over the last 12 months, three Avalyn Pharma Inc. the people running the company bought shares at market prices, about $25 million in total, and none of them sold.
Novo Holdings A/S (10% Owner) made the biggest buy, worth around $10 million.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 92 investment managers listed AVLN in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 5, 2026 | Novo Holdings A/S | 10% Owner | Buy | 555,555 | $18.00 | $10.0M | SEC |
| May 1, 2026 | Carroll Jill | Director | Buy | 277,778 | $18.00 | $5.0M | SEC |
| May 1, 2026 | George Simeon | 10% Owner | Buy | 277,777 | $18.00 | $5.0M | SEC |
| May 1, 2026 | George Simeon | 10% Owner | Buy | 277,778 | $18.00 | $5.0M | SEC |
In the last 12 months Avalyn Pharma Inc. insiders made open-market purchases worth about $25 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in AVLN was filed on 2026-05-05.
92 investment managers reported holding AVLN in SEC Form 13F filings for Q2 2026.
No congressional trades in AVLN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).